Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Androgen deprivation with or without docetaxel in non-metastatic prostate cancer with rising PSA
2008-003138-33Phase 3Completed
- Sponsor
- Scandinavian Prostate Cancer Group
- Start
- Sep 2008
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of docetaxel in prostate cancer (PCa) (2 arms), sponsored by Scandinavian Prostate Cancer Group. Primary endpoint: Progression-free survival. Started Sep 2008; status: completed.
02
Drugs
docetaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2008-003138-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003138-33.